Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Meningeal Neoplasms 1Medulloblastoma 1Hepatoblastoma 1

Interventions

Oxaliplatin 300Fluorouracil 272Bevacizumab 237Gemcitabine 236Leucovorin 212Capecitabine 207pembrolizumab 201Nivolumab 158Irinotecan 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 107Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
omburtamab I-131 × Gastrointestinal × 1 year × Clear all
NCT05064306 2025-08-01

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Memorial Sloan Kettering Cancer Center

No longer available
CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Medulloblastoma, Meningeal Neoplasms, Wilms Tumor, Neuroblastoma, Pinealoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡